Correlation of RET somatic mutations with clinicopathological features in sporadic medullary thyroid carcinomas
- PMID: 19401695
- PMCID: PMC2695700
- DOI: 10.1038/sj.bjc.6605056
Correlation of RET somatic mutations with clinicopathological features in sporadic medullary thyroid carcinomas
Abstract
Screening of REarranged during Transfection (RET) gene mutations has been carried out in different series of sporadic medullary thyroid carcinomas (MTC). RET-positive tumours seem to be associated to a worse clinical outcome. However, the correlation between the type of RET mutation and the patients' clinicopathological data has not been evaluated yet. We analysed RET exons 5, 8, 10-16 in fifty-one sporadic MTC, and found somatic mutations in thirty-three (64.7%) tumours. Among the RET-positive cases, exon 16 was the most frequently affected (60.6%). Two novel somatic mutations (Cys630Gly, c.1881del18) were identified. MTC patients were divided into three groups: group 1, with mutations in RET exons 15 and 16; group 2, with other RET mutations; group 3, having no RET mutations. Group 1 had higher prevalence (P=0.0051) and number of lymph node metastases (P=0.0017), and presented more often multifocal tumours (P=0.037) and persistent disease at last control (P=0.0242) than group 2. Detectable serum calcitonin levels at last screening (P=0.0119) and stage IV disease (P=0.0145) were more frequent in group 1, than in the other groups. Our results suggest that, among the sporadic MTC, cases with RET mutations in exons 15 and 16 are associated with the worst prognosis. Cases with other RET mutations have the most indolent course, and those with no RET mutations have an intermediate risk.
References
-
- André S, Pinto AE, Laranjeira C, Quaresma M, Soares J (2007) Male and female breast cancer − differences in DNA ploidy, p21 and p53 expression reinforce the possibility of distinct pathways of oncogenesis. Pathobiology 74: 323–327 - PubMed
-
- Bockhorn M, Frilling A, Kalinin V, Schröder S, Broelsch CE (1999) No correlation between RET immunostaining and the codon 918 mutation in sporadic medullary thyroid carcinoma. Langenbecks Arch Surg 384: 60–64 - PubMed
-
- Bugalho MJ, Coelho I, Sobrinho LG (2000) Somatic trinucleotide change encompassing codons 882 and 883 of the RET proto-oncogene in a patient with sporadic medullary thyroid carcinoma. Eur J Endocrinol 142: 573–575 - PubMed
-
- Bugalho MJ, Frade JP, Santos JR, Limbert E, Sobrinho L (1997) Molecular analysis of the RET proto-oncogene in patients with sporadic medullary thyroid carcinoma: a novel point mutation in the extracellular cysteine-rich domain. Eur J Endocrinol 136: 423–426 - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
